You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEpoprostenol
Accession NumberDB01240  (APRD00949)
TypeSmall Molecule
GroupsApproved
DescriptionA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Structure
Thumb
Synonyms
(5Z,13e)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,9alpha,11alpha,13e,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostenol
Flolan
PGI2
PGX
Prostacyclin
Prostaglandin I2
Prostaglandin x
Vasocyclin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Caripulpowder for solution1.5 mgintravenousActelion Pharmaceuticals Ltd2013-04-24Not applicableCanada
Caripulpowder for solution0.5 mgintravenousActelion Pharmaceuticals Ltd2013-04-24Not applicableCanada
Epoprostenol for Injectionpowder for solution0.5 mgintravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Epoprostenol for Injectionpowder for solution1.5 mgintravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Flolaninjection, powder, lyophilized, for solution.5 mg/1intravenousGlaxo Smith Kline Llc1995-12-08Not applicableUs
Flolaninjection, powder, lyophilized, for solution1.5 mg/1intravenousGlaxo Smith Kline Llc1995-12-08Not applicableUs
Flolanpowder for solution0.5 mgintravenousGlaxosmithkline Inc1997-07-28Not applicableCanada
Flolanpowder for solution1.5 mgintravenousGlaxosmithkline Inc1997-07-28Not applicableCanada
Veletriinjection, powder, lyophilized, for solution500000 ng/10mLintravenousActelion Pharmaceuticals US, Inc.2010-04-22Not applicableUs
Veletriinjection, powder, lyophilized, for solution1500000 ng/10mLintravenousActelion Pharmaceuticals US, Inc.2010-04-22Not applicableUs
Veletriinjection, powder, lyophilized, for solution1500000 ng/10mLintravenousActelion Pharmaceuticals US, Inc.2010-04-22Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Epoprostenol Sodiuminjection, powder, for solution.5 mg/1intravenousTeva Parenteral Medicines, Inc.2008-04-23Not applicableUs
Epoprostenol Sodiuminjection, powder, for solution1.5 mg/1intravenousTeva Parenteral Medicines, Inc.2008-04-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Epoprostenol sodium
ThumbNot applicableDBSALT001218
Categories
UNIIDCR9Z582X0
CAS number35121-78-9
WeightAverage: 352.4651
Monoisotopic: 352.224974134
Chemical FormulaC20H32O5
InChI KeyInChIKey=KAQKFAOMNZTLHT-OZUDYXHBSA-N
InChI
InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1
IUPAC Name
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-2-ylidene]pentanoic acid
SMILES
[H][C@]12C[C@@H](O)[[email protected]](\C=C\[C@@H](O)CCCCC)[C@@]1([H])CC(O2)=CCCCC(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Medium-chain hydroxy acid
  • Fatty alcohol
  • Medium-chain fatty acid
  • Heterocyclic fatty acid
  • Oxolane
  • Cyclic alcohol
  • Secondary alcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
PharmacodynamicsEpoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.
Mechanism of actionProstaglandins are present in most body tissues and fluids and mediate many biological functions. Epoprostenol (PGI2) is a member of the family of prostaglandins that is derived from arachidonic acid. The major pharmacological actions of epoprostenol is ultimately inhibition of platelet aggregation. Prostacyclin (PGI2) is released by healthy endothelial cells and performs its function through a paracrine signaling cascade that involves G protein-coupled receptors on nearby platelets and endothelial cells. The platelet Gs protein-coupled receptor (prostacyclin receptor) is activated when it binds to PGI2. This activation, in turn, signals adenylyl cyclase to produce cAMP. cAMP goes on to inhibit any undue platelet activation (in order to promote circulation) and also counteracts any increase in cytosolic calcium levels which would result from thromboxane A2 (TXA2) binding (leading to platelet activation and subsequent coagulation). PGI2 also binds to endothelial prostacyclin receptors and in the same manner raise cAMP levels in the cytosol. This cAMP then goes on to activate protein kinase A (PKA). PKA then continues the cascade by phosphorylating and inhibiting myosin light-chain kinase which leads to smooth muscle relaxation and vasodilation. Notably, PGI2 and TXA2 work as physiological antagonists.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 357 mL/kg
Protein bindingNot Available
Metabolism

Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.

SubstrateEnzymesProduct
Epoprostenol
Not Available
6,15-Diketo-13,14-dihydro-PGF1-alphaDetails
Epoprostenol
Not Available
6-Keto-PGF1-alphaDetails
Route of eliminationEpoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.
Half lifeThe in vitro half-life of epoprostenol in human blood at 37°C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.
ClearanceNot Available
ToxicitySymptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9922
Blood Brain Barrier+0.8767
Caco-2 permeable+0.5636
P-glycoprotein substrateSubstrate0.6946
P-glycoprotein inhibitor INon-inhibitor0.9131
P-glycoprotein inhibitor IINon-inhibitor0.8879
Renal organic cation transporterNon-inhibitor0.8878
CYP450 2C9 substrateNon-substrate0.8171
CYP450 2D6 substrateNon-substrate0.8622
CYP450 3A4 substrateSubstrate0.5384
CYP450 1A2 substrateNon-inhibitor0.5729
CYP450 2C9 inhibitorNon-inhibitor0.9251
CYP450 2D6 inhibitorNon-inhibitor0.9401
CYP450 2C19 inhibitorNon-inhibitor0.75
CYP450 3A4 inhibitorNon-inhibitor0.6126
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8673
Ames testNon AMES toxic0.7865
CarcinogenicityNon-carcinogens0.9555
BiodegradationNot ready biodegradable0.5964
Rat acute toxicity2.6928 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8304
hERG inhibition (predictor II)Non-inhibitor0.8759
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionintravenous.5 mg/1
Injection, powder, for solutionintravenous1.5 mg/1
Injection, powder, lyophilized, for solutionintravenous.5 mg/1
Injection, powder, lyophilized, for solutionintravenous1.5 mg/1
Powder for solutionintravenous0.5 mg
Powder for solutionintravenous1.5 mg
Injection, powder, lyophilized, for solutionintravenous1500000 ng/10mL
Injection, powder, lyophilized, for solutionintravenous500000 ng/10mL
Prices
Unit descriptionCostUnit
Flolan 1.5 mg vial51.59USD vial
Epoprostenol sodium 1.5 mg vial33.53USD vial
Flolan 0.5 mg vial21.36USD vial
Epoprostenol sodium 0.5 mg vial13.88USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8318802 No2007-03-152027-03-15Us
US8598227 No2007-02-022027-02-02Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.136 mg/mLALOGPS
logP3.83ALOGPS
logP2.42ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.43ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity99.01 m3·mol-1ChemAxon
Polarizability41.62 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Nagesh R. Palepu, “NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF.” U.S. Patent US20090088468, issued April 02, 2009.

US20090088468
General ReferencesNot Available
External Links
ATC CodesB01AC09
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (1.28 MB)
MSDSDownload (40.6 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Epoprostenol.
AbciximabEpoprostenol may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Epoprostenol can be decreased when combined with Abiraterone.
AcebutololAcebutolol may increase the hypotensive activities of Epoprostenol.
AceclofenacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Aceclofenac.
AcenocoumarolEpoprostenol may increase the anticoagulant activities of Acenocoumarol.
AcenocoumarolThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Epoprostenol.
Acetylsalicylic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Acetylsalicylic acid.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Acetylsalicylic acid.
AdapaleneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Adapalene.
AlfuzosinAlfuzosin may increase the hypotensive activities of Epoprostenol.
AliskirenEpoprostenol may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Epoprostenol.
AlprostadilAlprostadil may increase the anticoagulant activities of Epoprostenol.
AlprostadilEpoprostenol may increase the antiplatelet activities of Alprostadil.
AlteplaseEpoprostenol may increase the anticoagulant activities of Alteplase.
AlteplaseThe risk or severity of adverse effects can be increased when Alteplase is combined with Epoprostenol.
ALX-0081Epoprostenol may increase the anticoagulant activities of ALX-0081.
ALX-0081The risk or severity of adverse effects can be increased when ALX-0081 is combined with Epoprostenol.
AmbrisentanEpoprostenol may increase the hypotensive activities of Ambrisentan.
AmifostineEpoprostenol may increase the hypotensive activities of Amifostine.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Epoprostenol.
AmiodaroneThe metabolism of Epoprostenol can be decreased when combined with Amiodarone.
AmlodipineAmlodipine may increase the hypotensive activities of Epoprostenol.
AnagrelideAnagrelide may increase the anticoagulant activities of Epoprostenol.
AncrodEpoprostenol may increase the anticoagulant activities of Ancrod.
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Epoprostenol.
AnistreplaseEpoprostenol may increase the anticoagulant activities of Anistreplase.
AnistreplaseThe risk or severity of adverse effects can be increased when Anistreplase is combined with Epoprostenol.
AntipyrineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Antipyrine.
Antithrombin III humanEpoprostenol may increase the anticoagulant activities of Antithrombin III human.
ApixabanEpoprostenol may increase the anticoagulant activities of Apixaban.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Epoprostenol.
ApremilastThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Apremilast.
AprepitantThe metabolism of Epoprostenol can be increased when combined with Aprepitant.
AprotininThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Aprotinin.
ArdeparinEpoprostenol may increase the anticoagulant activities of Ardeparin.
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Epoprostenol.
ArgatrobanEpoprostenol may increase the anticoagulant activities of Argatroban.
AstaxanthinEpoprostenol may increase the anticoagulant activities of Astaxanthin.
AstaxanthinThe risk or severity of adverse effects can be increased when Astaxanthin is combined with Epoprostenol.
AtenololAtenolol may increase the hypotensive activities of Epoprostenol.
AzapropazoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azelastine.
AzelastineEpoprostenol may increase the antiplatelet activities of Azelastine.
BalsalazideThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Balsalazide.
BatroxobinEpoprostenol may increase the anticoagulant activities of Batroxobin.
BatroxobinThe risk or severity of adverse effects can be increased when Batroxobin is combined with Epoprostenol.
BecaplerminEpoprostenol may increase the anticoagulant activities of Becaplermin.
BemiparinEpoprostenol may increase the anticoagulant activities of Bemiparin.
BemiparinThe risk or severity of adverse effects can be increased when Bemiparin is combined with Epoprostenol.
BenazeprilBenazepril may increase the hypotensive activities of Epoprostenol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Epoprostenol.
BenmoxinBenmoxin may increase the hypotensive activities of Epoprostenol.
BenoxaprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Benoxaprofen.
BepridilEpoprostenol may increase the hypotensive activities of Bepridil.
BeraprostEpoprostenol may increase the anticoagulant activities of Beraprost.
BetaxololBetaxolol may increase the hypotensive activities of Epoprostenol.
BethanidineBethanidine may increase the hypotensive activities of Epoprostenol.
BimatoprostBimatoprost may increase the hypotensive activities of Epoprostenol.
BisoprololBisoprolol may increase the hypotensive activities of Epoprostenol.
BivalirudinEpoprostenol may increase the anticoagulant activities of Bivalirudin.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Epoprostenol.
BosentanBosentan may increase the hypotensive activities of Epoprostenol.
BretyliumBretylium may increase the hypotensive activities of Epoprostenol.
BrimonidineEpoprostenol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Epoprostenol.
BromfenacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bromfenac.
BupranololEpoprostenol may increase the hypotensive activities of Bupranolol.
CandesartanCandesartan may increase the hypotensive activities of Epoprostenol.
CandoxatrilCandoxatril may increase the hypotensive activities of Epoprostenol.
CangrelorEpoprostenol may increase the anticoagulant activities of Cangrelor.
CapecitabineThe metabolism of Epoprostenol can be decreased when combined with Capecitabine.
CaptoprilCaptopril may increase the hypotensive activities of Epoprostenol.
CarbamazepineThe metabolism of Epoprostenol can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Epoprostenol.
CarprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Epoprostenol.
CarvedilolCarvedilol may increase the hypotensive activities of Epoprostenol.
CastanospermineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Castanospermine.
CelecoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Celecoxib.
CeliprololEpoprostenol may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Epoprostenol can be increased when it is combined with Ceritinib.
CertoparinEpoprostenol may increase the anticoagulant activities of Certoparin.
ChloroquineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Epoprostenol.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Epoprostenol.
CholecalciferolThe metabolism of Epoprostenol can be decreased when combined with Cholecalciferol.
CilazaprilEpoprostenol may increase the hypotensive activities of Cilazapril.
CilostazolCilostazol may increase the anticoagulant activities of Epoprostenol.
Citric AcidEpoprostenol may increase the anticoagulant activities of Citric Acid.
ClonidineClonidine may increase the hypotensive activities of Epoprostenol.
ClonixinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Clonixin.
ClopidogrelClopidogrel may increase the anticoagulant activities of Epoprostenol.
ClotrimazoleThe metabolism of Epoprostenol can be decreased when combined with Clotrimazole.
CollagenaseThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Collagenase.
CryptenamineCryptenamine may increase the hypotensive activities of Epoprostenol.
CyclosporineThe metabolism of Epoprostenol can be decreased when combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Epoprostenol.
D-LimoneneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with D-Limonene.
Dabigatran etexilateEpoprostenol may increase the anticoagulant activities of Dabigatran etexilate.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Epoprostenol.
DabrafenibThe serum concentration of Epoprostenol can be decreased when it is combined with Dabrafenib.
DalteparinEpoprostenol may increase the anticoagulant activities of Dalteparin.
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Epoprostenol.
DanaparoidEpoprostenol may increase the anticoagulant activities of Danaparoid.
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Epoprostenol.
DasatinibDasatinib may increase the anticoagulant activities of Epoprostenol.
DebrisoquinEpoprostenol may increase the hypotensive activities of Debrisoquin.
DefibrotideEpoprostenol may increase the anticoagulant activities of Defibrotide.
DelavirdineThe metabolism of Epoprostenol can be decreased when combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Deoxycholic Acid.
DeserpidineEpoprostenol may increase the hypotensive activities of Deserpidine.
DesirudinEpoprostenol may increase the anticoagulant activities of Desirudin.
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Epoprostenol.
DesmoteplaseEpoprostenol may increase the anticoagulant activities of Desmoteplase.
DesmoteplaseThe risk or severity of adverse effects can be increased when Desmoteplase is combined with Epoprostenol.
DextranEpoprostenol may increase the anticoagulant activities of Dextran.
Dextran 40Epoprostenol may increase the anticoagulant activities of Dextran 40.
Dextran 70Epoprostenol may increase the anticoagulant activities of Dextran 70.
Dextran 75Epoprostenol may increase the anticoagulant activities of Dextran 75.
DiazoxideDiazoxide may increase the hypotensive activities of Epoprostenol.
DiclofenacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Diclofenac.
DicoumarolEpoprostenol may increase the anticoagulant activities of Dicoumarol.
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Epoprostenol.
DiflunisalThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Diflunisal.
DiflunisalThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Epoprostenol.
DiltiazemDiltiazem may increase the hypotensive activities of Epoprostenol.
DipyridamoleDipyridamole may increase the anticoagulant activities of Epoprostenol.
DitazoleEpoprostenol may increase the anticoagulant activities of Ditazole.
DitazoleThe risk or severity of adverse effects can be increased when Ditazole is combined with Epoprostenol.
DorzolamideDorzolamide may increase the hypotensive activities of Epoprostenol.
DoxazosinDoxazosin may increase the hypotensive activities of Epoprostenol.
Drotrecogin alfaEpoprostenol may increase the anticoagulant activities of Drotrecogin alfa.
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Epoprostenol.
DroxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Droxicam.
Edetic AcidEpoprostenol may increase the anticoagulant activities of Edetic Acid.
EdoxabanEpoprostenol may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Epoprostenol can be decreased when combined with Efavirenz.
EfonidipineEpoprostenol may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Epoprostenol.
EnalaprilatEpoprostenol may increase the hypotensive activities of Enalaprilat.
EnoxaparinEpoprostenol may increase the anticoagulant activities of Enoxaparin.
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Epoprostenol.
EpinastineEpinastine may increase the anticoagulant activities of Epoprostenol.
EpinastineEpoprostenol may increase the antiplatelet activities of Epinastine.
EpirizoleThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Epirizole.
EprosartanEprosartan may increase the hypotensive activities of Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Epoprostenol.
EtanerceptThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etanercept.
Ethyl biscoumacetateEpoprostenol may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Epoprostenol.
EtodolacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etofenamate.
EtoricoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etoricoxib.
EtravirineThe metabolism of Epoprostenol can be decreased when combined with Etravirine.
Evening primrose oilThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Evening primrose oil.
exisulindThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with exisulind.
FelodipineFelodipine may increase the hypotensive activities of Epoprostenol.
FenbufenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Epoprostenol.
FenoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenoprofen.
FibrinolysinEpoprostenol may increase the anticoagulant activities of Fibrinolysin.
FibrinolysinThe risk or severity of adverse effects can be increased when Fibrinolysin is combined with Epoprostenol.
FloctafenineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Floctafenine.
FloxuridineThe metabolism of Epoprostenol can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Epoprostenol can be decreased when combined with Fluconazole.
FlunixinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Flunixin.
FluorouracilThe metabolism of Epoprostenol can be decreased when combined with Fluorouracil.
FlurbiprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Flurbiprofen.
FluvastatinThe metabolism of Epoprostenol can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Epoprostenol can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumEpoprostenol may increase the anticoagulant activities of Fondaparinux sodium.
FosinoprilFosinopril may increase the hypotensive activities of Epoprostenol.
FosphenytoinThe metabolism of Epoprostenol can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Epoprostenol.
GemfibrozilThe metabolism of Epoprostenol can be decreased when combined with Gemfibrozil.
GlucosamineGlucosamine may increase the antiplatelet activities of Epoprostenol.
GuanabenzGuanabenz may increase the hypotensive activities of Epoprostenol.
GuanadrelGuanadrel may increase the hypotensive activities of Epoprostenol.
GuanethidineGuanethidine may increase the hypotensive activities of Epoprostenol.
GuanfacineGuanfacine may increase the hypotensive activities of Epoprostenol.
HeparinEpoprostenol may increase the anticoagulant activities of Heparin.
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Epoprostenol.
HexamethoniumEpoprostenol may increase the hypotensive activities of Hexamethonium.
HirulogEpoprostenol may increase the anticoagulant activities of Hirulog.
HMPL-004The therapeutic efficacy of Epoprostenol can be decreased when used in combination with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Epoprostenol.
HydralazineEpoprostenol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Epoprostenol.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Epoprostenol.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Epoprostenol.
IbudilastIbudilast may increase the anticoagulant activities of Epoprostenol.
IbudilastEpoprostenol may increase the antiplatelet activities of Ibudilast.
IbuprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Icatibant.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Epoprostenol.
Icosapent ethylEpoprostenol may increase the antiplatelet activities of Icosapent ethyl.
IfenprodilIfenprodil may increase the anticoagulant activities of Epoprostenol.
IfenprodilEpoprostenol may increase the antiplatelet activities of Ifenprodil.
IloprostIloprost may increase the hypotensive activities of Epoprostenol.
IloprostEpoprostenol may increase the anticoagulant activities of Iloprost.
IndapamideIndapamide may increase the hypotensive activities of Epoprostenol.
IndenololEpoprostenol may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Epoprostenol can be decreased when combined with Indinavir.
IndomethacinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indoprofen.
IndoraminEpoprostenol may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Epoprostenol.
IproniazidIproniazid may increase the hypotensive activities of Epoprostenol.
IrbesartanIrbesartan may increase the hypotensive activities of Epoprostenol.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Epoprostenol.
IsoxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Epoprostenol.
KebuzoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Kebuzone.
KetoconazoleThe metabolism of Epoprostenol can be decreased when combined with Ketoconazole.
KetoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Epoprostenol.
LacidipineEpoprostenol may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Epoprostenol.
LeflunomideThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Leflunomide.
LepirudinEpoprostenol may increase the anticoagulant activities of Lepirudin.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Epoprostenol.
LercanidipineLercanidipine may increase the hypotensive activities of Epoprostenol.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Epoprostenol.
LisinoprilLisinopril may increase the hypotensive activities of Epoprostenol.
LofexidineEpoprostenol may increase the hypotensive activities of Lofexidine.
LornoxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Epoprostenol.
LovastatinThe metabolism of Epoprostenol can be decreased when combined with Lovastatin.
LoxoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Loxoprofen.
LumacaftorThe serum concentration of Epoprostenol can be decreased when it is combined with Lumacaftor.
LumiracoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lumiracoxib.
MacitentanEpoprostenol may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Magnesium salicylate.
ManidipineEpoprostenol may increase the hypotensive activities of Manidipine.
MasoprocolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Epoprostenol.
MecamylamineMecamylamine may increase the hypotensive activities of Epoprostenol.
Meclofenamic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid.
Mefenamic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mefenamic acid.
MeloxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Mesalazine.
MetamizoleThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Metamizole.
MethyldopaMethyldopa may increase the hypotensive activities of Epoprostenol.
Methylene blueMethylene blue may increase the hypotensive activities of Epoprostenol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Epoprostenol.
MetipranololMetipranolol may increase the hypotensive activities of Epoprostenol.
MetolazoneMetolazone may increase the hypotensive activities of Epoprostenol.
MetoprololMetoprolol may increase the hypotensive activities of Epoprostenol.
MibefradilEpoprostenol may increase the hypotensive activities of Mibefradil.
MifepristoneThe serum concentration of Epoprostenol can be increased when it is combined with Mifepristone.
MilrinoneMilrinone may increase the anticoagulant activities of Epoprostenol.
MilrinoneEpoprostenol may increase the antiplatelet activities of Milrinone.
MinaprineMinaprine may increase the hypotensive activities of Epoprostenol.
MinoxidilMinoxidil may increase the hypotensive activities of Epoprostenol.
MoclobemideMoclobemide may increase the hypotensive activities of Epoprostenol.
MoexiprilMoexipril may increase the hypotensive activities of Epoprostenol.
MolsidomineMolsidomine may increase the hypotensive activities of Epoprostenol.
MoxonidineEpoprostenol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolic acid.
NabumetoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nabumetone.
NadololNadolol may increase the hypotensive activities of Epoprostenol.
NadroparinEpoprostenol may increase the anticoagulant activities of Nadroparin.
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Epoprostenol.
NaftifineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Naftifine.
NaproxenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Naproxen.
NCX 4016The therapeutic efficacy of Epoprostenol can be decreased when used in combination with NCX 4016.
NCX 4016Epoprostenol may increase the anticoagulant activities of NCX 4016.
NebivololEpoprostenol may increase the hypotensive activities of Nebivolol.
NepafenacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Epoprostenol.
NicardipineNicardipine may increase the hypotensive activities of Epoprostenol.
NicorandilEpoprostenol may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Niflumic Acid.
NiguldipineEpoprostenol may increase the hypotensive activities of Niguldipine.
NilvadipineEpoprostenol may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nimesulide.
NimesulideEpoprostenol may increase the antiplatelet activities of Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Epoprostenol.
NisoldipineNisoldipine may increase the hypotensive activities of Epoprostenol.
NitrendipineNitrendipine may increase the hypotensive activities of Epoprostenol.
NitroprussideNitroprusside may increase the hypotensive activities of Epoprostenol.
ObinutuzumabThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Epoprostenol.
OlmesartanOlmesartan may increase the hypotensive activities of Epoprostenol.
OlopatadineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Epoprostenol.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Epoprostenol.
OmeprazoleThe metabolism of Epoprostenol can be decreased when combined with Omeprazole.
OrgoteinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Orgotein.
OtamixabanEpoprostenol may increase the anticoagulant activities of Otamixaban.
OxaprozinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxaprozin.
OxprenololEpoprostenol may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxyphenbutazone.
ParecoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Parecoxib.
PargylineEpoprostenol may increase the hypotensive activities of Pargyline.
ParnaparinEpoprostenol may increase the anticoagulant activities of Parnaparin.
ParnaparinThe risk or severity of adverse effects can be increased when Parnaparin is combined with Epoprostenol.
PenbutololEpoprostenol may increase the hypotensive activities of Penbutolol.
PentoliniumPentolinium may increase the hypotensive activities of Epoprostenol.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epoprostenol.
Pentosan PolysulfateEpoprostenol may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Epoprostenol.
PerindoprilPerindopril may increase the hypotensive activities of Epoprostenol.
PhenelzinePhenelzine may increase the hypotensive activities of Epoprostenol.
PhenindioneEpoprostenol may increase the anticoagulant activities of Phenindione.
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Epoprostenol.
PheniprazinePheniprazine may increase the hypotensive activities of Epoprostenol.
PhenobarbitalThe metabolism of Epoprostenol can be increased when combined with Phenobarbital.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Epoprostenol.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Epoprostenol.
PhenprocoumonEpoprostenol may increase the anticoagulant activities of Phenprocoumon.
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Epoprostenol.
PhentolaminePhentolamine may increase the hypotensive activities of Epoprostenol.
PhenylbutazoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Phenylbutazone.
PhenytoinThe metabolism of Epoprostenol can be increased when combined with Phenytoin.
PimecrolimusThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pimecrolimus.
PinacidilEpoprostenol may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Epoprostenol.
PirfenidoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Epoprostenol.
PiroxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Epoprostenol.
PlasminEpoprostenol may increase the anticoagulant activities of Plasmin.
PlasminThe risk or severity of adverse effects can be increased when Plasmin is combined with Epoprostenol.
PolythiazideEpoprostenol may increase the hypotensive activities of Polythiazide.
PrasugrelEpoprostenol may increase the anticoagulant activities of Prasugrel.
PrazosinPrazosin may increase the hypotensive activities of Epoprostenol.
PrimidoneThe metabolism of Epoprostenol can be increased when combined with Primidone.
PropacetamolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Epoprostenol.
Protein CEpoprostenol may increase the anticoagulant activities of Protein C.
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Epoprostenol.
ProtocatechualdehydeEpoprostenol may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The therapeutic efficacy of Epoprostenol can be decreased when used in combination with PTC299.
PyrimethamineThe metabolism of Epoprostenol can be decreased when combined with Pyrimethamine.
QuinaprilQuinapril may increase the hypotensive activities of Epoprostenol.
QuinineQuinine may increase the hypotensive activities of Epoprostenol.
RamiprilRamipril may increase the hypotensive activities of Epoprostenol.
RasagilineRasagiline may increase the hypotensive activities of Epoprostenol.
RemikirenRemikiren may increase the hypotensive activities of Epoprostenol.
RescinnamineEpoprostenol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Epoprostenol.
ResveratrolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Resveratrol.
ResveratrolEpoprostenol may increase the antiplatelet activities of Resveratrol.
ReteplaseEpoprostenol may increase the anticoagulant activities of Reteplase.
ReteplaseThe risk or severity of adverse effects can be increased when Reteplase is combined with Epoprostenol.
ReviparinEpoprostenol may increase the anticoagulant activities of Reviparin.
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Epoprostenol.
RidogrelRidogrel may increase the anticoagulant activities of Epoprostenol.
RidogrelEpoprostenol may increase the antiplatelet activities of Ridogrel.
RifampicinThe metabolism of Epoprostenol can be increased when combined with Rifampicin.
RifapentineThe metabolism of Epoprostenol can be increased when combined with Rifapentine.
RiociguatEpoprostenol may increase the hypotensive activities of Riociguat.
RituximabEpoprostenol may increase the hypotensive activities of Rituximab.
RivaroxabanEpoprostenol may increase the anticoagulant activities of Rivaroxaban.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Epoprostenol.
RofecoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Rofecoxib.
RosiglitazoneEpoprostenol may increase the anticoagulant activities of Rosiglitazone.
RosiglitazoneThe risk or severity of adverse effects can be increased when Rosiglitazone is combined with Epoprostenol.
SafrazineSafrazine may increase the hypotensive activities of Epoprostenol.
SalicylamideThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salicylic acid.
Salicylic acidThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Salicylic acid.
SalsalateThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salsalate.
SaprisartanEpoprostenol may increase the hypotensive activities of Saprisartan.
SCH-530348SCH-530348 may increase the anticoagulant activities of Epoprostenol.
SCH-530348Epoprostenol may increase the antiplatelet activities of SCH-530348.
SecobarbitalThe metabolism of Epoprostenol can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Epoprostenol.
SelexipagEpoprostenol may increase the hypotensive activities of Selexipag.
SeratrodastThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Seratrodast.
SevofluraneSevoflurane may increase the anticoagulant activities of Epoprostenol.
SevofluraneEpoprostenol may increase the antiplatelet activities of Sevoflurane.
SildenafilSildenafil may increase the antihypertensive activities of Epoprostenol.
SitaxentanEpoprostenol may increase the hypotensive activities of Sitaxentan.
SorafenibThe metabolism of Epoprostenol can be decreased when combined with Sorafenib.
SpiraprilEpoprostenol may increase the hypotensive activities of Spirapril.
SRT501The therapeutic efficacy of Epoprostenol can be decreased when used in combination with SRT501.
SRT501Epoprostenol may increase the antiplatelet activities of SRT501.
StreptokinaseEpoprostenol may increase the anticoagulant activities of Streptokinase.
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Epoprostenol.
SulfadiazineThe metabolism of Epoprostenol can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Epoprostenol can be decreased when combined with Sulfamethoxazole.
SulfasalazineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulfasalazine.
SulfisoxazoleThe metabolism of Epoprostenol can be decreased when combined with Sulfisoxazole.
SulindacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulindac.
SulodexideEpoprostenol may increase the anticoagulant activities of Sulodexide.
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Epoprostenol.
SuprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Epoprostenol.
TelmisartanTelmisartan may increase the hypotensive activities of Epoprostenol.
TemocaprilEpoprostenol may increase the hypotensive activities of Temocapril.
TenecteplaseEpoprostenol may increase the anticoagulant activities of Tenecteplase.
TenecteplaseThe risk or severity of adverse effects can be increased when Tenecteplase is combined with Epoprostenol.
TenoxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tepoxalin.
TeriflunomideThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Teriflunomide.
TerlipressinEpoprostenol may increase the hypotensive activities of Terlipressin.
TesmilifeneTesmilifene may increase the anticoagulant activities of Epoprostenol.
TesmilifeneEpoprostenol may increase the antiplatelet activities of Tesmilifene.
Tiaprofenic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tiaprofenic acid.
TiboloneEpoprostenol may increase the hypotensive activities of Tibolone.
TicagrelorEpoprostenol may increase the anticoagulant activities of Ticagrelor.
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Epoprostenol.
TiclopidineTiclopidine may increase the anticoagulant activities of Epoprostenol.
TicrynafenEpoprostenol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Epoprostenol.
TinzaparinEpoprostenol may increase the anticoagulant activities of Tinzaparin.
TinzaparinThe risk or severity of adverse effects can be increased when Tinzaparin is combined with Epoprostenol.
TipranavirTipranavir may increase the antiplatelet activities of Epoprostenol.
TirofibanTirofiban may increase the anticoagulant activities of Epoprostenol.
TolazolineTolazoline may increase the hypotensive activities of Epoprostenol.
TolbutamideThe metabolism of Epoprostenol can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Epoprostenol.
TorasemideTorasemide may increase the hypotensive activities of Epoprostenol.
TositumomabThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tositumomab.
TrandolaprilTrandolapril may increase the hypotensive activities of Epoprostenol.
TranilastThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tranilast.
TranilastEpoprostenol may increase the antiplatelet activities of Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Epoprostenol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Epoprostenol.
TrapidilTrapidil may increase the anticoagulant activities of Epoprostenol.
TrapidilEpoprostenol may increase the antiplatelet activities of Trapidil.
TravoprostTravoprost may increase the hypotensive activities of Epoprostenol.
TreprostinilTreprostinil may increase the hypotensive activities of Epoprostenol.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Epoprostenol.
TriflusalEpoprostenol may increase the anticoagulant activities of Triflusal.
TrimazosinEpoprostenol may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Epoprostenol.
TrimethoprimThe metabolism of Epoprostenol can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Epoprostenol.
UnoprostoneEpoprostenol may increase the hypotensive activities of Unoprostone.
UrokinaseEpoprostenol may increase the anticoagulant activities of Urokinase.
UrokinaseThe risk or severity of adverse effects can be increased when Urokinase is combined with Epoprostenol.
ValdecoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Valdecoxib.
Valproic AcidThe metabolism of Epoprostenol can be decreased when combined with Valproic Acid.
ValsartanValsartan may increase the hypotensive activities of Epoprostenol.
VardenafilVardenafil may increase the antihypertensive activities of Epoprostenol.
Vitamin EVitamin E may increase the antiplatelet activities of Epoprostenol.
VorapaxarEpoprostenol may increase the anticoagulant activities of Vorapaxar.
VoriconazoleThe metabolism of Epoprostenol can be decreased when combined with Voriconazole.
WarfarinEpoprostenol may increase the anticoagulant activities of Warfarin.
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Epoprostenol.
XimelagatranEpoprostenol may increase the anticoagulant activities of Ximelagatran.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Epoprostenol.
XylometazolineEpoprostenol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Epoprostenol.
ZafirlukastThe metabolism of Epoprostenol can be decreased when combined with Zafirlukast.
ZaltoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zileuton.
ZomepiracThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name:
P2RY12
Uniprot ID:
Q9H244
Molecular Weight:
39438.355 Da
References
  1. Cattaneo M, Lecchi A: Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost. 2007 Mar;5(3):577-82. Epub 2006 Dec 7. [PubMed:17155953 ]
  2. Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, Woulfe D, Brass LF: Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem. 2002 Nov 29;277(48):46035-42. Epub 2002 Sep 23. [PubMed:12297509 ]
  3. Kobsar AL, Koessler J, Rajkovic MS, Brunner KP, Steigerwald U, Walter U: Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system. Platelets. 2010;21(2):112-6. doi: 10.3109/09537100903440937. [PubMed:20085435 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name:
PTGIR
Uniprot ID:
P43119
Molecular Weight:
40955.485 Da
References
  1. Kasza Z, Fetalvero KM, Ding M, Wagner RJ, Acs K, Guzman AK, Douville KL, Powell RJ, Hwa J, Martin KA: Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94. doi: 10.1016/j.yjmcc.2009.01.006. Epub 2009 Jan 23. [PubMed:19302827 ]
  2. Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, Woulfe D, Brass LF: Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem. 2002 Nov 29;277(48):46035-42. Epub 2002 Sep 23. [PubMed:12297509 ]
  3. Ibrahim S, Tetruashvily M, Frey AJ, Wilson SJ, Stitham J, Hwa J, Smyth EM: Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1802-9. doi: 10.1161/ATVBAHA.110.208900. Epub 2010 Jun 3. [PubMed:20522800 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Prostaglandin-i synthase activity
Specific Function:
Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).
Gene Name:
PTGIS
Uniprot ID:
Q16647
Molecular Weight:
57103.385 Da
References
  1. Nakayama T: Genetic polymorphisms of prostacyclin synthase gene and cardiovascular disease. Int Angiol. 2010 Apr;29(2 Suppl):33-42. [PubMed:20357747 ]
  2. Ruan KH, Wu J, Cervantes V: Characterization of the substrate mimic bound to engineered prostacyclin synthase in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of prostacyclin. Biochemistry. 2008 Jan 15;47(2):680-8. Epub 2007 Dec 15. [PubMed:18081314 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:26